Satisfaction with botulinum toxin treatment: A cross-sectional survey of patients with cervical dystonia

Kapil Dev Sethi, Ramon Rodriguez, Babajide Olayinka

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective: Botulinum toxin is widely utilized as a first-line therapy for cervical dystonia (CD). Numerous studies have demonstrated the efficacy and safety of this treatment, but little data exist on patient satisfaction. To address this question, a structured patient survey was conducted in Germany, France, the US, and Canada (n=136 patients with CD). Methods: Specific information was collected on the patients' current and prior botulinum toxin treatment cycles and their overall quality-of-life (including completion of the Cervical Dystonia Impact Profile-58 [CDIP-58]). Results: Patients rated the mean onset of action for their previous injection as 3.8 days, with peak effect at 3.6 weeks and a decline in effects at 9.5 weeks. While most patients were satisfied with their current therapy, only 50.7% were very satisfied, 42.6% were somewhat satisfied, and 6.6% not at all satisfied with their current therapy. Patient satisfaction was lowest just prior to injection and highest at the time of peak effect. Approximately 45% of patients reported that they would prefer a treatment cycle of ≤10 weeks. The mean patient rating of current state of health was above 50 on a visual analog scale from 0 (low) to 100 (high). CDIP-58 results indicated that patients continued to have symptoms on all domains. Conclusions: Botulinum toxin is generally very effective for the treatment of CD. However, this survey indicates that patient satisfaction typically declines prior to re-injection, and many patients may prefer an injection interval of less than the standard 12 weeks. While the survey was based on subjective patient recollections, and the degree to which patient satisfaction is attributable to the control of neurological symptoms remains unclear, prospective studies are clearly warranted to confirm the time course of patient satisfaction and to determine the optimal treatment parameters with botulinum toxins.

Original languageEnglish (US)
Pages (from-to)419-423
Number of pages5
JournalJournal of Medical Economics
Volume15
Issue number3
DOIs
StatePublished - Jun 1 2012

Fingerprint

Torticollis
Type A Botulinum Toxins
Cross-Sectional Studies
Patient Satisfaction
Botulinum Toxins
Therapeutics
Injections
Visual Analog Scale
France
Canada
Germany
Quality of Life
Prospective Studies
Safety

Keywords

  • AbobotulinumtoxinA
  • Botox
  • Cervical dystonia
  • Dysport
  • IncobotulinumtoxinA
  • OnabotulinumtoxinA
  • Xeomin

ASJC Scopus subject areas

  • Health Policy

Cite this

Satisfaction with botulinum toxin treatment : A cross-sectional survey of patients with cervical dystonia. / Sethi, Kapil Dev; Rodriguez, Ramon; Olayinka, Babajide.

In: Journal of Medical Economics, Vol. 15, No. 3, 01.06.2012, p. 419-423.

Research output: Contribution to journalArticle

Sethi, Kapil Dev ; Rodriguez, Ramon ; Olayinka, Babajide. / Satisfaction with botulinum toxin treatment : A cross-sectional survey of patients with cervical dystonia. In: Journal of Medical Economics. 2012 ; Vol. 15, No. 3. pp. 419-423.
@article{3a61498872e54d478a62c905f0eb4119,
title = "Satisfaction with botulinum toxin treatment: A cross-sectional survey of patients with cervical dystonia",
abstract = "Objective: Botulinum toxin is widely utilized as a first-line therapy for cervical dystonia (CD). Numerous studies have demonstrated the efficacy and safety of this treatment, but little data exist on patient satisfaction. To address this question, a structured patient survey was conducted in Germany, France, the US, and Canada (n=136 patients with CD). Methods: Specific information was collected on the patients' current and prior botulinum toxin treatment cycles and their overall quality-of-life (including completion of the Cervical Dystonia Impact Profile-58 [CDIP-58]). Results: Patients rated the mean onset of action for their previous injection as 3.8 days, with peak effect at 3.6 weeks and a decline in effects at 9.5 weeks. While most patients were satisfied with their current therapy, only 50.7{\%} were very satisfied, 42.6{\%} were somewhat satisfied, and 6.6{\%} not at all satisfied with their current therapy. Patient satisfaction was lowest just prior to injection and highest at the time of peak effect. Approximately 45{\%} of patients reported that they would prefer a treatment cycle of ≤10 weeks. The mean patient rating of current state of health was above 50 on a visual analog scale from 0 (low) to 100 (high). CDIP-58 results indicated that patients continued to have symptoms on all domains. Conclusions: Botulinum toxin is generally very effective for the treatment of CD. However, this survey indicates that patient satisfaction typically declines prior to re-injection, and many patients may prefer an injection interval of less than the standard 12 weeks. While the survey was based on subjective patient recollections, and the degree to which patient satisfaction is attributable to the control of neurological symptoms remains unclear, prospective studies are clearly warranted to confirm the time course of patient satisfaction and to determine the optimal treatment parameters with botulinum toxins.",
keywords = "AbobotulinumtoxinA, Botox, Cervical dystonia, Dysport, IncobotulinumtoxinA, OnabotulinumtoxinA, Xeomin",
author = "Sethi, {Kapil Dev} and Ramon Rodriguez and Babajide Olayinka",
year = "2012",
month = "6",
day = "1",
doi = "10.3111/13696998.2011.653726",
language = "English (US)",
volume = "15",
pages = "419--423",
journal = "Journal of Medical Economics",
issn = "1369-6998",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Satisfaction with botulinum toxin treatment

T2 - A cross-sectional survey of patients with cervical dystonia

AU - Sethi, Kapil Dev

AU - Rodriguez, Ramon

AU - Olayinka, Babajide

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Objective: Botulinum toxin is widely utilized as a first-line therapy for cervical dystonia (CD). Numerous studies have demonstrated the efficacy and safety of this treatment, but little data exist on patient satisfaction. To address this question, a structured patient survey was conducted in Germany, France, the US, and Canada (n=136 patients with CD). Methods: Specific information was collected on the patients' current and prior botulinum toxin treatment cycles and their overall quality-of-life (including completion of the Cervical Dystonia Impact Profile-58 [CDIP-58]). Results: Patients rated the mean onset of action for their previous injection as 3.8 days, with peak effect at 3.6 weeks and a decline in effects at 9.5 weeks. While most patients were satisfied with their current therapy, only 50.7% were very satisfied, 42.6% were somewhat satisfied, and 6.6% not at all satisfied with their current therapy. Patient satisfaction was lowest just prior to injection and highest at the time of peak effect. Approximately 45% of patients reported that they would prefer a treatment cycle of ≤10 weeks. The mean patient rating of current state of health was above 50 on a visual analog scale from 0 (low) to 100 (high). CDIP-58 results indicated that patients continued to have symptoms on all domains. Conclusions: Botulinum toxin is generally very effective for the treatment of CD. However, this survey indicates that patient satisfaction typically declines prior to re-injection, and many patients may prefer an injection interval of less than the standard 12 weeks. While the survey was based on subjective patient recollections, and the degree to which patient satisfaction is attributable to the control of neurological symptoms remains unclear, prospective studies are clearly warranted to confirm the time course of patient satisfaction and to determine the optimal treatment parameters with botulinum toxins.

AB - Objective: Botulinum toxin is widely utilized as a first-line therapy for cervical dystonia (CD). Numerous studies have demonstrated the efficacy and safety of this treatment, but little data exist on patient satisfaction. To address this question, a structured patient survey was conducted in Germany, France, the US, and Canada (n=136 patients with CD). Methods: Specific information was collected on the patients' current and prior botulinum toxin treatment cycles and their overall quality-of-life (including completion of the Cervical Dystonia Impact Profile-58 [CDIP-58]). Results: Patients rated the mean onset of action for their previous injection as 3.8 days, with peak effect at 3.6 weeks and a decline in effects at 9.5 weeks. While most patients were satisfied with their current therapy, only 50.7% were very satisfied, 42.6% were somewhat satisfied, and 6.6% not at all satisfied with their current therapy. Patient satisfaction was lowest just prior to injection and highest at the time of peak effect. Approximately 45% of patients reported that they would prefer a treatment cycle of ≤10 weeks. The mean patient rating of current state of health was above 50 on a visual analog scale from 0 (low) to 100 (high). CDIP-58 results indicated that patients continued to have symptoms on all domains. Conclusions: Botulinum toxin is generally very effective for the treatment of CD. However, this survey indicates that patient satisfaction typically declines prior to re-injection, and many patients may prefer an injection interval of less than the standard 12 weeks. While the survey was based on subjective patient recollections, and the degree to which patient satisfaction is attributable to the control of neurological symptoms remains unclear, prospective studies are clearly warranted to confirm the time course of patient satisfaction and to determine the optimal treatment parameters with botulinum toxins.

KW - AbobotulinumtoxinA

KW - Botox

KW - Cervical dystonia

KW - Dysport

KW - IncobotulinumtoxinA

KW - OnabotulinumtoxinA

KW - Xeomin

UR - http://www.scopus.com/inward/record.url?scp=84859207456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859207456&partnerID=8YFLogxK

U2 - 10.3111/13696998.2011.653726

DO - 10.3111/13696998.2011.653726

M3 - Article

C2 - 22208596

AN - SCOPUS:84859207456

VL - 15

SP - 419

EP - 423

JO - Journal of Medical Economics

JF - Journal of Medical Economics

SN - 1369-6998

IS - 3

ER -